Houston Car Accident Lawyers
A Risperdal trial that led to a verdict for the defense was overturned by a Pennsylvania Superior Court who ordered a new trial. The plaintiff in the original Risperdal trial alleged that he developed gynecomastia after taking the medication. The patient alleges severe and painful injuries after receiving a prescription for Risperdal.
A three-judge panel of the Pennsylvania Superior Court reversed the only verdict that favored drug manufacturer Johnson & Johnson and allowed the plaintiff to receive a new trial.
The case originally concluded in March of 2015 when a jury identified that Janssen Pharmaceuticals and Johnson & Johnson had not properly warned doctors and patients about the risks of developing gynecomastia, otherwise known as excessive male breast growth with other critical side effects.
According to the Risperdal trial, the jurors were unable to reach a conclusion that Risperdal was the cause of the plaintiff’s gynecomastia and therefore, denied that plaintiff financial damages.
The unanimous decision from the superior court panel, however, was released on Nov. 13, 2017 and identified that the trial court had allowed a physician’s assistant who had been involved in treatment with the plaintiff to testify as an expert witness. A new Risperdal trial was ordered limited only to handling issues of damages and causation.
Lawsuits Connect Risperdal to Gynecomastia
More than 6,000 Risperdal lawsuits have already been filed by patients who started taking the popular antipsychotic medication and began to grow breasts. The vast majority of the Risperdal lawsuits allege the development of gynecomastia, a condition known for permanent and excessive growth of breast tissue in boys and men.
In addition to breast development, other symptoms may include breast tenderness, nipple discharge or even signs of lactation. Many of these patients who have initiated a Risperdal lawsuit have done so because of the advanced surgical interventions required to discontinue the growth, including mastectomy and liposuction.
According to Risperdal lawsuits, the pituitary gland is triggered to generate excessive amounts of prolactin, a hormone known to initiate female breast development.
Johnson & Johnson had previously characterized this condition as a rare side effect that had been seen in fewer than one out of every 1,000 patients. However, a 2006 label change on the medication indicated that 2.3 percent of male adolescents who had taken Risperdal also developed gynecomastia.
The development of gynecomastia may cause physical and emotional problems for a young man, particularly if it requires surgery or other advanced treatment options to remove the side effects of the condition.
If you or someone you know developed gynecomastia or other severe symptoms as a result of taking Risperdal, you may have grounds to pursue an injury claim.
The experienced attorneys at McDonald Worley offer a free case evaluation. Call today!